• Atomo to raise up to $4.0 million via placement and share purchase plan
• Placement of $3.0 million to institutional and sophisticated investors
• Share Purchase Plan of up to $1.0 million for eligible shareholders

Atomo Diagnostics Limited (ASX: AT1) has announced that it has completed a capital raising of up to $4.0 million. The capital raising comprises a $3.0 million placement to institutional and sophisticated professional investors, and a $1.0 million share purchase plan (SPP) for eligible shareholders. The placement will result in the issuance of approximately 90.9 million new fully paid ordinary shares at an issue price of $0.033 (3.3 cents) per share, with 45.5 million free attaching options exercisable at $0.045 (4.5 cents) and expiring in 2.5 years. The issue price represents a 10% discount to the 15-day volume-weighted average price. The net proceeds from the capital raising, together with the company's existing cash balance of approximately $3.5 million as of 31 December 2025, will fund the company through to early 2028. The funds will be used to expand the commercialization of Atomo's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale-up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US, and provide working capital alongside the costs of the capital raising.

The additional capital enables the company to expand commercialization of Atomo's own portfolio of proprietary diagnostic tests, deliver operational scale-up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US, and support new 'Atomo inside' customers and Atomo's own products.